natgillin/translations-raw huggingface dataset:
The most frequently reported adverse reactions ( &gt; 10 %) with brivaracetam treatment were: somnolence (14.3 %) and dizziness (11.0 %).
Najčešće prijavljene nuspojave ( &gt; 10%) kod liječenja brivaracetamom bile su somnolencija (14,3%) i omaglica (11,0%).
The most frequently reported adverse reactions ( &gt; 10%) with brivaracetam treatment were: somnolence (14.3 %) and dizziness (11.0 %).
Najčešće prijavljene nuspojave ( &gt; 10%) kod liječenja brivaracetamom bile su somnolencija (14,3%) i omaglica (11,0%).
The most frequently reported adverse reactions ( &gt; 5%) during glycerol phenylbutyrate treatment were diarrhoea, flatulence, and headache (8.8% each); decreased appetite (7.0%), vomiting (6.1%); and fatigue, nausea and, skin odour abnormal (5.3% each).
Najčešće prijavljene nuspojave ( &gt; 5%) tijekom liječenja glicerolfenilbutiratom bile su proljev, flatulencija i glavobolja (svaka 8,8%); smanjen apetit (7,0%), povraćanje (6,1%); i umor, mučnina te neuobičajen miris kože (svaka 5,3%).
The most pronounced increases were observed in patients of low body weight ( &lt; 30 kg).
Najizrazitija povećanja bila su opažena u bolesnika male tjelesne težine ( &lt; 30 kg).
The most relevant fracture reduction was observed among patients at high risk of fractures such as patients with previous fractures and in patients with a lumbar spine T-score of &lt; - 3.
Najvažnije smanjenje rizika prijeloma primijećeno je u bolesnica sa visokim rizikom prijeloma, kao što su bolesnice s prethodnim prijelomima i bolesnice s T-vrijednošću lumbalne kralježnice ≤ -3.
The most resistant variants with single amino acid substitution in genotype 2a and genotype 3a were F28S (EC50 &gt; 300 nM) and Y93H (EC50 &gt; 1,000 nM), respectively.
Najrezistentnije varijante sa samo jednom aminokiselinskom zamjenom u genotipu 2a odnosno genotipu 3a bile su F28S (EC50 &gt; 300 nM) odnosno Y93H (EC50 &gt; 1000 nM).
The most serious adverse reaction reported in clinical trials with deferiprone is agranulocytosis (neutrophils &lt; 0.5x109/l), with an incidence of 1.1% (0.6 cases per 100 patient-years of treatment) (see section 4.4).
Najozbiljnija nuspojava prijavljena u kliničkim ispitivanjima s deferipronom je agranulocitoza (neutrofili &lt; 0,5x109/l), s incidencijom od 1,1% (0,6 slučajeva na 100 bolesnika-godina liječenja) (vidjeti dio 4.4).
The multicentre trial included 5 paediatric patients ( &lt; 18 years old), 3 of whom achieved CR.
Multicentrično ispitivanje uključivalo je 5 pedijatrijskih bolesnika (mlađih od 18 godina), od kojih su 3 postigla potpunu remisiju.
The neutralising antibody responses in subjects &gt; 60 years were as follows:
Odgovor neutralizirajućih protutijela u ispitanika dobne skupine &gt; 60 godina bio je sljedeći:
The neutropenia observed was reversible and not cumulative; the mean time to nadir was 13 days and the mean time to recovery from severe neutropenia ( &lt; 0.5 x 109/l) was 8 days.
Primijećena neutropenija bila je reverzibilna i nije bila kumulativna; prosječno vrijeme smanjenja broja neutrofila na najniže vrijednosti iznosilo je 13 dana, a prosječno vrijeme do oporavka od teške neutropenije ( &lt; 0,5 x 109/l) iznosilo je 8 dana.
The NO2 concentration should be maintained as low as possible and always &lt; 0.5 ppm.
Koncentracija NO2 mora biti što niža, a uvijek mora biti &lt; 0,5 ppm.
The NOAEL for fertility, early embryonic development and teratogenicity in rats was set at &gt; 900 times the human exposure.
NOAEL za plodnost, rani razvoj embrija i teratogenost kod štakora postavljen je na doze &gt; 900 puta više od izloženosti kod ljudi.
The NOAEL was &lt; 200 mg/kg/day for the dams and 200 mg/kg/day for the fetuses (equal to the MRHD on a mg/m2 basis).
NOAEL je za gravidne ženke iznosila &lt; 200 mg/kg/dan, a za fetuse 200 mg/kg/dan (što je jednako MRHD-u, Maximum Recommended Human Dose, izraženom u mg/m2).
The NOAEL was &lt; 200 mg/kg/day for the dams and 200 mg/kg/day for the fetuses (equal to the MRHD on a mg/m2 basis).
NOAEL je za gravidne ženke iznosila &lt; 200 mg/kg/dan, a za fetuse 200 mg/kg/dan (što je jednako najvećoj preporučenoj dozi u ljudi izraženoj u mg/m2).
The NOAEL was &lt; 200 mg/kg/day for the dams and 200 mg/kg/day for the foetuses (equal to the MRHD on a mg/m2 basis).
NOAEL je za gravidne ženke iznosila &lt; 200 mg/kg/dan, a za fetuse 200 mg/kg/dan (što je jednako MRHD-u, Maximum Recommended Human Dose, izraženom u mg/m2).
The nosocomial pneumonia (NP) studies excluded known or suspected pulmonary disease like granulomatous diseases, lung cancer, or other malignancy metastatic to the lungs; cystic fibrosis or active tuberculosis; Legionella pneumophila pneumonia; meningitis, endocarditis, or osteomyelitis; refractory shock defined as supine systolic blood pressure &lt; 90 mm Hg for &gt; 2 hours with evidence of hypoperfusion or requirement for high-dose sympathomimetic agents.
Ispitivanja bolničke pneumonije isključila su poznate plućne bolesti ili one na koje se sumnja kao što su granulomske bolesti, rak pluća ili druge maligne metastaze na plućima; cistična fibroza ili aktivna tuberkuloza, upala pluća uzrokovana bakterijom Legionella pneumophila; meningitis, endokarditis ili osteomijelitis; refraktorni šok definiran kao ležeći sistolički krvi tlak &lt; 90 mm Hg tijekom &gt; 2 sata uz prisutnost hipoperfuzije ili zahtijeva visoke doze simpatomimetičnih tvari.
The number of normal sperm was significantly reduced ( &lt; 10%) relative to controls and the percent abnormal sperm (detached heads or no heads) were significantly increased (up to 3%).
Broj normalnih spermija bio je značajno smanjen ( &lt; 10%) u odnosu na kontrolnu skupinu i postotak abnormalnih spermija (s odvojenim glavama ili bez glava) bio značajno povećan (do 3%).
The number of patients who returned to a normal IIEF domain score ( &gt; 26) were 53% on vardenafil compared to 9% on placebo.
Postotak bolesnika u kojih se vratio normalan rezultat prema IIEF indeksu ( &gt; 26) iznosio je 53% uz vardenafil u usporedbi s 9% uz placebo.
The number of patients who returned to a normal IIEF domain score ( &gt; 26) were 53% on vardenafil compared to 9% on placebo.
Postotak bolesnika u kojih se vratio normalan rezultat prema IIEF indeksu (≥ 26) iznosio je 53% uz vardenafil u usporedbi s 9% uz placebo.
The number of patients who returned to a normal IIEF domain score ( &gt; 26) were 53% on vardenafil compared to 9% on placebo.
Postotak bolesnika u kojih se vratio normalan rezultat prema IIEF indeksu (≥26) iznosio je 53% uz vardenafil u usporedbi s 9% uz placebo.
The number of patients with viral load &lt; 50 copies/mL was 9 of 13 for the same period.
U istom je razdoblju 9 od 13 bolesnika imalo količinu virusa od &lt; 50 kopija/ml.
The objective response rate (complete response [CR] plus partial response [PR]) per independent radiological review was significantly (p &lt; 0.0001) higher in the lenvatinib-treated group (64.8%) than in the placebo-treated group (1.5%).
Prema neovisnom radiološkom pregledu, stopa objektivnog odgovora (potpuni odgovor plus djelomični odgovor) bila je značajno (p &lt; 0,0001) viša u skupini liječenoj lenvatinibom (64,8%) nego u skupini koja je primala placebo (1,5%).
The observed ACR 20 response rate at this timepoint was 91%.The reduction (RA-I) from Baseline in DAS28 (ESR) also was significantly greater (p &lt; 0.001) at Week 52 (RA-I) and Week 24 (RA-II) compared to placebo and maintained through 2 years in the open-label extension trial to RA-I.
Smanjenje (RA-I) u odnosu na početno stanje u DAS28 (ESR) također je bilo značajno više (p &lt; 0,001) nakon 52 tjedna (RA-I) te nakon 24 tjedna (RA-II) u odnosu na placebo i ono je održavano kroz sljedeće 2 godine u otvorenom produžetku istraživanja RA-I.
The observed benefit of prasugrel in patients ≥ 75 years was less than that observed in patients &lt; 75 years.
Korist liječenja prasugrelom u bolesnika u dobi od ≥ 75 godina bila je manja od one u bolesnika mlađih od 75 godina.
The observed incidence of the less severe form of neutropenia (neutrophils &lt; 1.5x109/l) is 4.9% (2.5 cases per 100 patient-years).
Opažena incidencija manje teškog oblika neutropenije (neutrofili &lt; 1,5x109/l) je 4,9% (2,5 slučaja na 100 bolesnika-godina).
The observed treatment difference (95% CI) between ivacaftor and placebo was 10.7% (7.3, 14.1) (P &lt; 0.0001).
Opažena terapijska razlika (95% CI) između ivakaftora i placeba iznosila je 10,7% (7,3; 14,1) (P &lt; 0,0001).
The observed WRC in pitolisant group was about half of WRC in the placebo group: the effect size of pitolisant compared with placebo was summarized by the ratio rate rR(Pt/Pb), rR=0.512; 95%CI [0.435 to 0.603]; p &lt; 0.0001).
Zabilježeni WRC u skupini koja je primala pitolizant iznosio je približno polovicu vrijednosti WRC-a skupine koja je primala placebo: opseg učinka pitolizanta u usporedbi s placebom izražen je relativnom stopom rR(Pt/Pb), rR=0,512; 95 %CI [0,435 do 0,603]; p &lt; 0,0001).
The occurrence of osteosarcoma only occurred at doses that produced systemic exposures &gt; 27-times higher than that observed in humans at the 100 micrograms dose.
Učestalost osteosarkoma primijećena je kod doza koje dovode do sistemske izloženosti 27 ili više puta veće od one zabilježene kod ljudi pri primjeni doze od 100 mikrograma.
The only vaccine-related systemic adverse reactions reported at a significantly greater rate in individuals who received the earlier formulation of ProQuad compared to individuals who received the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. and Varicella Vaccine live (Oka/Merck) were fever (≥39.4°C rectal equivalent or abnormal) and measles-like rash.
Jedina sustavna nuspojava povezana s cjepivom prijavljena u značajno većoj učestalosti u djece koja su primila raniji oblik cjepiva ProQuad nego u djece koja su primila cjepivo protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc. i živo cjepivo protiv varičele (Oka/Merck) bila je vrućica (≥39,4°C, rektalni ekvivalent ili abnormalna) i osip sličan morbilima.
The oral bioavailability of both fluticasone furoate and vilanterol was low, on average 1.26% and &lt; 2%, respectively.
Oralna bioraspoloživost flutikazonfuroata i vilanterola bila je niska, u prosjeku 1,26% odnosno &lt; 2%.
The oral median lethal dose (LD50) of tolvaptan in rats and dogs is &gt; 2000 mg/kg.
Medijan oralne smrtonosne doze (LD50) tolvaptana kod štakora i pasa je &gt; 2000 mg/kg.
The ORR was 27.9% and 0% for subjects in the cabozantinib arm and placebo arm, respectively (p &lt; 0.0001; Table 2).
ORR je iznosio 27,9% za skupinu ispitanika u kojih je primjenjivan kabozantinib i 0% za skupinu ispitanika u kojih je primjenjivan placebo (p &lt; 0,0001; Tablica 2).
The OS and PFS benefit was observed consistently, in all relevant pre-specified subgroups, including race, geographic region, age ( &lt; 65; ≥ 65), sex, ECOG PS, KRAS status, time since diagnosis of first metastasis, number of metastatic sites, and primary tumour site.
Korist u smislu OS i PFS je konzistentno zabilježena u svih relevantnih, prethodno specificiranih, podskupina, uključujući rasu, geografsku regiju, starost ( &lt; 65; ≥ 65), spol, ECOG PS, KRAS status, vrijeme od dijagnoze prve metastaze, broj metastatskih sjela i mjesto primarnog tumora.
The overall adverse reaction profile for morbidly obese patients (BMI &gt; 40) does not suggest a meaningful difference in safety compared to patients with BMI ≤ 40.
Ukupni profil nuspojava u morbidno pretilih bolesnika (indeks tjelesne mase, ITM &gt; 40) ne upućuje na značajnu razliku u sigurnosti u usporedbi s bolesnicima s ITM ≤40.
The overall exposure of adolescents (12 to ≤17 years) and children (2 to &lt; 12 years) to deferasirox after single and multiple doses was lower than that in adult patients.
Ukupna izloženost deferasiroksu adolescenata (12 do ≤17 godina) i djece (2 do &lt; 12 godina) nakon jednokratne i višestrukih doza bila je niža od one u odraslih bolesnika.
The overall incidence of transaminase increases &gt; 3 xULN (not necessarily comprising an adverse event) in the voriconazole clinical programme was 18.0% (319/1,768) in adults and 25.8% (73/283) in paediatric subjects who received voriconazole for pooled therapeutic and prophylaxis use.
Ukupna incidencija povećanja vrijednosti transaminaza &gt; 3 x ULN (ne nužno uključujući i nuspojavu) u ispitanika koji su u kliničkim ispitivanjima primali vorikonazol iznosila je 18,0% (319/1768) u odraslih i 25,8% (73/283) kod pedijatrijskih ispitanika koji su primili vorikonazol u kombiniranu terapeutsko-profilaktičku svrhu.
The overall incidence of transaminase increases &gt; 3 xULN (not necessarily comprising an adverse event) in the voriconazole clinical programme was 18.0% (319/1768) in adults and 25.8% (73/283) in paediatric subjects who received voriconazole for pooled therapeutic and prophylaxis use.
Ukupna incidencija povećanja vrijednosti transaminaza &gt; 3 x ULN (ne nužno uključujući i nuspojavu) u ispitanika koji su u kliničkim ispitivanjima primali vorikonazol iznosila je 18,0 % (319/1768) ) u odraslih i 25,8% (73/283) kod pedijatrijskih ispitanika koji su primili vorikonazol u kombiniranu terapeutsko- profilaktičku svrhu.
The overall incidence of transaminase increases &gt; 3xULN (not necessarily comprising an adverse event) in the voriconazole clinical programme was 18.0% (319/1,768) in adults and 25.8% (73/283) in paediatric subjects who received voriconazole for pooled therapeutic and prophylaxis use.
Ukupna incidencija povećanja vrijednosti transaminaza &gt; 3 x ULN (ne nužno uključujući i nuspojavu) u ispitanika koji su u kliničkim ispitivanjima primali vorikonazol iznosila je 18,0 % (319/1768) u odraslih i 25,8 % (73/238) kod pedijatrijskih ispitanika koji su primili vorikonazol u kombiniranu terapeutsko-profilaktičku svrhu.
The overall objective response rates in the all-randomised population (investigator assessment) were 25.7% (capecitabine) vs.
Ukupni terapijski odgovor u cijeloj randomiziranoj populaciji (prema prosudbi istraživača) bio je 25,7% (kapecitabin) nasuprot 16,7% (Mayo protokol), p &lt; 0,0002.
The overall rate of response (ICC and EC combined) was 88.9% (8/9) for 2 to &lt; 12 years old and 62.5% (5/8) for 12 to &lt; 18 years old.
Ukupna stopa reakcije (ICC i EC zajedno) bila je 88,9% (8/9) za bolesnike u dobi od 2 do &lt; 12 godina i 62,5% (5/8) za bolesnike u dobi od 12 do &lt; 18 godina.
The overall survival hazard ratio in patients &lt; 65 years of age was 0.68 (95% CI 0.55, 0.85) and in patients 65 years of age and older it was 0.95 (95% CI 0.76, 1.19).
Omjer hazarda za ukupno preživljenje u bolesnika u dobi ispod 65 godina bio je 0,68 (95% CI 0,55; 0,85), a u bolesnika starih 65 godina i više bio je 0,95 (95% CI 0,76; 1,19).
The overall therapeutic response rate also was similar for the daptomycin and SOC treatment arms for infections caused by MRSA, MSSA and Streptococcus pyogenes (see table below; ME population); response rates were &gt; 94% for both treatment arms across these common pathogens.
Stopa ukupnog terapijskog odgovora bila je slična i za skupine liječene daptomicinom i standardnom skrbi za infekcije uzrokovane MRSA-om, MSSA-om i bakterijom Streptococcus pyogenes (vidjeti tablicu u nastavku; mikrobiološki ocjenjiva populacija); stope odgovora bile su &gt; 94% za obje liječene skupine za sve ove česte patogene.
The patients had at least one additional coronary heart disease risk factor, including: previous myocardial infarction or stroke ( &gt; 6 months prior to enrollment) or documentation of other atherosclerotic cardiovascular disease (overall 51.5 %), type 2 diabetes (36.1 %), high density lipoprotein - cholesterol &lt; 35 mg/dl or &lt; 0.906 mmol/l (11.6 %), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9 %), current cigarette smoking (21.9 %).
Bolesnici su imali najmanje jedan dodatni faktor rizika za koronarnu bolest srca, uključujući prethodni infarkt miokarda ili moždani udar ( &gt; 6 mjeseci prije uključivanja u ispitivanje) ili dokumentaciju o drugoj aterosklerotskoj kardiovaskularnoj bolesti (ukupno 51,5%), šećernu bolest tipa 2 (36,1%), lipoprotein visoke gustoće - kolesterol &lt; 35 mg/dl ili &lt; 0,906 mmol/l (11,6%), hipertrofiju lijevog ventrikula dijagnosticiranu elektrokardiogramom ili ehokardiografijom (20,9%), aktivni status pušača (21,9%).
The patients had at least one additional coronary heart disease risk factor, including: previous myocardial infarction or stroke ( &gt; 6 months prior to enrollment) or documentation of other atherosclerotic cardiovascular disease (overall 51.5%), type 2 diabetes (36.1%), high density lipoprotein - cholesterol &lt; 35 mg/dl or &lt; 0.906 mmol/l (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).
Bolesnici su imali najmanje jedan dodatni faktor rizika za koronarnu bolest srca, uključujući prethodni infarkt miokarda ili moždani udar ( &gt; 6 mjeseci prije uključivanja u ispitivanje) ili dokumentaciju o drugoj aterosklerotskoj kardiovaskularnoj bolesti (ukupno 51,5%), šećernu bolest tip 2 (36,1%), lipoprotein visoke gustoće - kolesterol &lt; 35 mg/dl ili &lt; 0,906 mmol/l (11,6%), hipertrofiju lijevog ventrikula dijagnosticiranu elektrokardiogramom ili ehokardiografijom (20,9%), aktivni status pušača (21,9%).
The patients had at least one additional coronary heart disease risk factor, including: previous myocardial infarction or stroke ( &gt; 6 months prior to enrollment) or documentation of other atherosclerotic cardiovascular disease (overall 51.5%), type 2 diabetes (36.1%), high density lipoprotein - cholesterol &lt; 35 mg/dl or &lt; 0.906 mmol/l (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).
Bolesnici su imali najmanje jedan dodatni faktor rizika za koronarnu bolest srca, uključujući prethodni infarkt miokarda ili moždani udar ( &gt; 6 mjeseci prije uključivanja u ispitivanje) ili dokumentaciju o drugoj aterosklerotskoj kardiovaskularnoj bolesti (ukupno 51,5%), šećernu bolest tipa 2 (36,1%), lipoprotein visoke gustoće - kolesterol &lt; 35 mg/dl ili &lt; 0,906 mmol/l (11,6%), hipertrofiju lijevog ventrikula dijagnosticiranu elektrokardiogramom ili ehokardiografijom (20,9%), aktivni status pušača (21,9%).
The percentage of patients achieving biochemical control, including those patients with IGF-1 &lt; LLN was 25.9% in the pasireotide intramuscular use group and 0% in the octreotide intramuscular use group.
Postotak bolesnika koji su postigli biokemijsku kontrolu, uključujući one bolesnike s IGF-1 &lt; DGN bio je 25,9% u skupini koja je primala pasireotid intramuskularno i 0% u skupini koja je primala oktreotid intramuskularno.
The percentage of patients achieving HIV-1 RNA &lt; 50 copies/ml at Week 24 was lower in the paediatric patients receiving lopinavir/ritonavir tablets once daily (88.2%) than in patients receiving the twice-daily dosing (96.6%, p = 0.040), mainly due to lower adherence in the once-daily group.
Postotak bolesnika koji su postigli HIV-1 RNK &lt; 50 kopija/ml u 24. tjednu je bio niži u pedijatrijskih bolesnika koji su primali lopinavir/ritonavir tablete jednom dnevno (88,2%) u odnosu na bolesnike koji su primali lopinavir/ritonavir dvaput na dan (96,6%, p = 0,040), uglavnom zbog slabije suradljivosti radi neredovitijeg uzimanja lijeka u skupini koja je primala lijek jednom dnevno.
The percentage of patients achieving HIV-1 RNA &lt; 50 copies/ml at Week 24 was lower in the paediatric patients receiving lopinavir/ritonavir tablets once daily (88.2%) than in patients receiving the twice-daily dosing (96.6%, p = 0.040), mainly due to lower adherence in the once-daily group.
Postotak bolesnika koji su postigli HIV-1 RNK &lt; 50 kopija/ml u 24. tjednu je bio niži u pedijatrijskih bolesnika koji su primali lopinavir/ritonavir tablete jednom dnevno (88,2%) u odnosu na bolesnike koji su primali lopinavir/ritonavir dvaput na dan (96,6%, p=0,040), uglavnom zbog slabije suradljivosti radi neredovitijeg uzimanja lijeka u skupini koja je primala lijek jednom dnevno.
The percentage of patients in AUGMENT who achieved a clinically meaningful improvement from baseline in SGRQ total score (defined as a decrease of at least 4 units) was higher with Brimica Genuair than with placebo (58.2% compared to 38.7%, respectively; p &lt; 0.001).
Postotak bolesnika u ispitivanju AUGMENT koji su postigli klinički značajno poboljšanje od početne vrijednosti u SGRQ ukupnom rezultatu (definirano kao smanjenje od najmanje 4 jedinice) bio je veći s Brimica Genuairom nego s placebom (58,2% u usporedbi s 38,7%; p &lt; 0,001).
The percentage of patients in AUGMENT who achieved a clinically meaningful improvement from baseline in SGRQ total score (defined as a decrease of at least 4 units) was higher with Duaklir Genuair than with placebo (58.2% compared to 38.7%, respectively; p &lt; 0.001).
Postotak bolesnika u ispitivanju AUGMENT koji su postigli klinički značajno poboljšanje od početne vrijednosti u SGRQ ukupnom rezultatu (definirano kao smanjenje od najmanje 4 jedinice) bio je veći s Duaklir Genuairom nego s placebom (58,2% u usporedbi s 38,7%; p &lt; 0,001).
The percentage of patients with Grades 3-4 neutropenia (neutrophil counts &lt; 0.75 x 109/L) was higher in boceprevir-treated patients (29%) than in placebo-treated patients (17%), in combination with peginterferon alfa-2b and ribavirin.
Postotak bolesnika s neutropenijom stupnja 3-4 (broj neutrofila &lt; 0,75 x 109/l) bio je veći u skupinama liječenima boceprevirom (29%) nego u bolesnika koji su primali placebo (17%) u kombinaciji s peginterferonom alfa-2b i ribavirinom.
The percentage of patients with heart rate values &lt; 50 bpm on treatment was 11% for patients who received lumacaftor/ivacaftor, compared to 4.9% for patients who received placebo.
Postotak bolesnika s vrijednostima frekvencije srca &lt; 50 otkucaja po minuti tijekom liječenja iznosio je 11% za bolesnike koji su primali lumakaftor/ivakaftor, u usporedbi s 4,9% za bolesnike koji su primali placebo.
The percentage of patients with vitamin D deficiency (serum 25-hydroxyvitamin D  22.5 nmol/l [ 9 ng/ml]) was significantly reduced by 92 % with FOSAVANCE (70 mg/2,800 IU) vs. alendronate-only (1 % vs 13 %, respectively).
Postotak ispitanica s manjkom vitamina D (25-hidroksivitamin D &lt; 22,5 nmol/l [ &lt; 9 ng/ml] u serumu) značajno je smanjen za 92% u skupini koja je primala FOSAVANCE (70 mg/2800 IU) naspram skupine koja je primala samo alendronat (1% naspram 13%).
The percentage of patients with vitamin D insufficiency (serum 25-hydroxyvitamin D &lt; 37.5 nmol/l
Do 15. tjedna postotak bolesnica s nedostatkom vitamina D (25-hidroksivitamin D &lt; 37,5 nmol/l [ &lt; 15 ng/ml] u serumu) u skupini koja je primala
The percentage of subjects reaching neutralising antibody titres of &gt; 1/80 were 54.9% and 44.9% at months 12 and 24, respectively.
Postotak osoba koje su dosegle titar neutralizirajućih protutijela &gt; 1/80 u 12. mjesecu bio je 54,9%, a u 24. mjesecu 44,9%.
The percentage of subjects with baseline viral loads &gt; 100,000 copies/ml was 39.7%.
Postotak ispitanika s početnim virusnim opterećenjem od &gt; 100 000 kopija/ml iznosio je 39,7%.
The percentage of the dose of lenvatinib excreted in urine was low in all cohorts ( &lt; 2.16% across treatment cohorts).
Postotak doze lenvatiniba izlučen mokraćom bio je nizak u svim kohortama ( &lt; 2,16% u svakoj terapijskoj kohorti).
The percentage of thrice-weekly urine samples that were negative for non-study opioids was statistically higher for both buprenorphine/naloxone versus placebo (p &lt; 0.0001) and buprenorphine versus placebo (p &lt; 0.0001).
Postotak uzoraka urina uzorkovanih tri puta tjedno koji su bili negativni na opioide izvan ispitivanja, bio je statistički veći za buprenorfin/nalokson u usporedbi s placebom (p &lt; 0,0001), i za buprenorfin u usporedbi s placebom (p &lt; 0,0001).